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a 3 cm graft was removed and cleared from the boundaw tissue, so that 
it became sulfidentty thin. A Palmaz or a Palmaz-Schatz slant was then 
covered by the vein graft. Thirteen AVGCSs were implanted percutaneously 
through a 10F guiding catheter in 13 pts suffering from angina (12 male, 1 
female, mean age 58 4- g years). Two AVGCSs were tcwplanted in by-pass 
vein grafts, 2 in the left anterior descending artery, 8 tn the right coronary 
adery, and one in the left elmumflex. Quantitative coronary angiography was 
performed to measure the minimal uminal diameter (MLD). The pts were 
discharged from the hospital under anticoagulaticn treatment. Results: De- 
ployment of the AVGCS was successful in all caseS, The mean MLD was 
incraesad from 0.41 :E 0.t to 3.2f ± 0.2 mm (p < 0.001). No complications 
were encountered uring the procedure. The TST was negative in all 4 pts, 
that underwent he examination. All I~tS were free of angina at a follow-up 
period of 4.2 :E 1.5 monthS. Conclusion: Implantation of AVGCS in humans 
is a feasible procedure with excellent immediate results. Further studies 
am warranted, however, to investigate the efficacy of AVGCS, in terms of 
reducing the incidence of acute thrombosis and late mstenosia. 
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~ Prognostic Value of  History of  Congestive Heart a 
Failure in Patients Undergoing Pereutaneous 
Coronary Interventions 
R. David Anderson, Nancy M. Wildermann, David R. Holmes Jr., 
Christopher M, O'Conner, Robert A. Harrington, Hany R, PhillipS, Robert 
M. Califf, E. Magnus Ohman. Duke University, Durham, NC 
To evaluate the clinical and engiogrephiC outcomes in pts with LV dysfunction 
undergoing PTCA/DCA with and without symptoms of CHF we examined 
2017 pts. Pts were pooled from 4 muiticenter tdals with 6 to 9 me follow-up 
and grouped according to EF: < 30%, 30-40%, and > 40%. Pts with reduced 
EF were morn frequently male (89°/= vs 77% vs 73%), had more CHF (48% 
vs 17% vs 9%), previous CABG (48% vs 27% vs 15%), MI (79% vs 83% vs 
51%) and 3-vessel disease (13% vs 11% vs 6%). Pts with EF < 30% had 
lower procedural success (QCA stenosia _< 50%) rates (61% vs 81% vs 81%) 
but similar restenosfs rates HIP/o vs 47% vs 47%). Mortality and composite 
outcome (death, MI, CABG and repeat PTCA) were: 
EF < 30% EF 30-40% EF > 40% 
-CHF 'H3HF -CHF +CHF -CHF +CHF 
n -24  n=S2 n=153 n=31 n= 1671 n=gg 
Death (30 d) 8% 14% 1% 3% 1% 2% 
Death (e me) 17% 32% 3°4, 6% 1% 4% 
Comp (9 me) 46% 64% 34% 39% 37% 28% 
Muitivariable logistic regression showed no association between EF/CHF 
and 9 me rates of MI, CABG or PTCA. A significant association between 
mortality and EF (x 2 = 23, p = 0.0001) and history of CHF (x 2 = 24, p = 
0.006) was obsewed. A clinical history of CHF added to EF (p = 0.02) in 
predicting 9 me mortality. In conclusion, CHF history and EF am important 
clinical variables that portend poor eady and late outcomes in pts undergoing 
percuteneous interventions. 
4:15 
~ Intravaecular Ultrasound Evidence for  Balloon 
Oversizlng in Diabetics: A Factor in Higher 
Complication Rates? 
Anthony C. De France, E. Murat Tuzcu, Kheled M. Zinda, William 
A, Magyar, Nirav Shah, David J. Molitemo, Patrick L. Whitlow, Irving France, 
Stephen G. Ellis, Steven E. Nissen. Cleveland Clinic, OH 
Objectives: Diabetic paflents have higher beiton angioplasCy complication 
rates and increased risk of mstenosis. We sought to determine whether 
dilfersnces in vessel size or morphology by intravasculer ultrasound could 
explain this phenomenon. 
Methods: We evaluated 313 interventions in244 patients who underwent 
primary or adjunctive balloon angiopiasty. Angiographie and ultrasound lumi- 
nal diameters, media-edvenUUa diameter and area, and degrees of arc with 
calcification were measured at "normal" reference sites adjacent to target 
lesions. Measurements were pedorrned in a laboratory blinded to clinical 
variables. Patients with a history' of diabetes were compared to patients 
without known diabetes 
Recurs: Relerence Sttes Diabetes No Diabetes jo 
n = 46 n = 267 value 
Angto Lumen Diameter (ram) 3.36 3,35 NS 
Ultrasour~ Lumen Diameter tram) 3,15 3.21 NS 
Maximum Balloon Size (ram) 3A3 3.47 NS 
Extent of Cs~t ion  (degrees) 33.6 19.t 0.0005 
Media-Adventltls Area (ram 2) 12.77 14.07 0.02 
Salloon/Aegio Diameter Ralio 1,02 1.04 NS 
Bagoon/IVUS Media Ratio 0.86 0.82 0.03 
Conc/asior~: Thus, diabetic and non-diabetic patients have compara~e 
engiagraphtc and ultrasound mr..fence vessel diameters, are dilated with 
similar balloon sizes, and have cempamble ratios of balloon size to anglo- 
graphic reference diameter, Hnwever, diabetics have much higher likelihood 
of ultrasound-detected calcification and have a significantly smaller media- 
adventttia area by ultrasound, This phenomenon results in a significantly 
higher balloon to media ratio which may explain the higher complication 
rates in clinical studies, 
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~ Immediate and Long-Term Clinical Outcome in 
Patients Undergoing Angioplasty of Occluded Vein 
Grafts 
Peter B. Berger, Malcolm R. Bell, Robert Simari, Guy S. Reeder, Diane 
E. Grill, David R. Holmes Jr.. Mayo C/In/c, Rochester, MN 
To determine the immediate and long-term clinical outcome associated with 
PTCA of occluded vein grafts, we analyzed 77 consecutive patients (LotS) 
without an MI 3 24 hours in whom PTCA of an occluded vein graft was 
attempted. New devices (slants, atherectomy, or laser) were used in 48=/° of 
procedures; intravascuiar thmmbolytic therapy was used in 23%. Myocardial 
infarcticn (MI) had occurred 1 to 7 days pdor to PTCA in 22 pts (29%). Mean 
age was 65 yrs: 8"P/O were male. Class 3 or 4 angina was present in 85=/o; 
79% had a prior MI, 26% had a hx of CHR Mean graft age was 7.5 =k 3.9 
yrs. Angiographic success (< 50% residual stenosis) was achieved in 71% 
of procedures (in 68=/= of pts with a recent MI vs 73% in the remaining lOtS). 
The 30 day mortality was 5.2%; 1% of pts suffered a Q wave MI and 8% 
underwent repeat CABG within 30 days. Univariate analysis indicated that 
the graft age, but not angiographio failure, was associated with death and MI 
throughout he hospitalization and foflow-up period. During follow-up (mean 
2.0 ~: 1.9 yrs), them was no difference in 3 yr survival between pts in whom 
angiographtc success had and had not been achieved (68% vs 76%), nor 
was them a difference in freedom from either MI (75% vs 74%), repeat PTCA 
or CABG (49% vs 48%) orthe development of severe angina (36% vs 42=/o). 
We conclude that PTCA of occluded vein grafts is successful in only 71% of 
cases, event rates am high in the subsequent 30 days, and when successful, 
adveme events dudng the following 3 year~ am no less frequent han in pts 
in whom PTCA was unsuccessful. Randomized trials comparing PTCA to 
repeat CABG and medical therapy in such pts am needed. 
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~ Clinical Outcome of  "High-Risk" vs  "Elective" 
Patients Undergoing Percutaneous Coronary 
Intervention: Results f rom IMPACTdl 
James J. Fergusen, Timothy J. McDonough, Seth J. Wodey, William 
J. French, John C. CorbeUi, James C, Blankenship, Daniel Carey, Frank 
V. Aguirre, Robert A, Harrington, J David Talley, A. Michael Lincetf, William 
C. Sheldon, Bonnie H. Weiner, Jan R. Resar, James E. Tcheng, Eric 
J. Topoi, Robert M. Califf on behalf of the IMPACT-II Investigators, Texas 
Heart Institute, Houston, TX 
IMPACT-II was a randomized, plecabo-controfled trial of two doses of the 
GP lib/ilia blocker, lntegmlin, in 4010 patients undergoing PTCA, with pa- 
tients stratified at enrollment to either a"high-risk" (unstable angina with EKG 
changes or acute MI) or"elective" ann. Paradoxically, Integmlin appeared to 
reduce adverse outcome events (30~ay combined rate of death, MI, or ur- 
gent revascutatizaticn) inelective but not high-risk patients. Moreover, event 
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